176 related articles for article (PubMed ID: 35201961)
21. Identification of Multidimensional Phenotypes Using Cluster Analysis in Sarcoid Uveitis Patients.
Fermon C; El-Jammal T; Kodjikian L; Burillon C; Hot A; Pérard L; Mathis T; Jamilloux Y; Sève P
Am J Ophthalmol; 2022 Oct; 242():107-115. PubMed ID: 35752321
[TBL] [Abstract][Full Text] [Related]
22. Uveitis in sarcoidosis.
Uyama M
Int Ophthalmol Clin; 2002; 42(1):143-50. PubMed ID: 12189610
[TBL] [Abstract][Full Text] [Related]
23. Increased Aqueous Humor CD4+/CD8+ Lymphocyte Ratio in Sarcoid Uveitis.
Dave N; Chevour P; Mahendradas P; Venkatesh A; Kawali A; Shetty R; Ghosh A; Sethu S
Ocul Immunol Inflamm; 2019; 27(7):1033-1040. PubMed ID: 29420111
[No Abstract] [Full Text] [Related]
24. Unusual Presentation of Skin Tattoo-Associated Panuveitis.
Alisi L; Armentano M; Sampalmieri L; Bruschi S; Zito R; Iannetti L
Ocul Immunol Inflamm; 2023 Apr; 31(3):653-655. PubMed ID: 35226585
[TBL] [Abstract][Full Text] [Related]
25. Factors Predicting Visual Acuity Outcome in Intermediate, Posterior, and Panuveitis: The Multicenter Uveitis Steroid Treatment (MUST) Trial.
Kempen JH; Van Natta ML; Altaweel MM; Dunn JP; Jabs DA; Lightman SL; Thorne JE; Holbrook JT;
Am J Ophthalmol; 2015 Dec; 160(6):1133-1141.e9. PubMed ID: 26386159
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic categorization according to the First International Workshop on Ocular Sarcoidosis (FIWOS) criteria in a series of 11 patients.
Meneses CF; Egües CA; Uriarte M; Errazquin N; Valero Jaimes A; Maíz O; Belzunegui J; Blanco A
Reumatol Clin; 2017; 13(1):25-29. PubMed ID: 26948714
[TBL] [Abstract][Full Text] [Related]
27. Clinical features and visual outcomes of ocular sarcoidosis at a tertiary referral center in Tokyo.
Nagahori K; Keino H; Nakayama M; Watanabe T; Ando Y; Hayashi I; Abe S; Okada AA
Graefes Arch Clin Exp Ophthalmol; 2022 Oct; 260(10):3357-3363. PubMed ID: 35616725
[TBL] [Abstract][Full Text] [Related]
28. Pediatric Non-Infectious Uveitis: Long-Term Outcomes and Complications.
Markomichelakis NN; Aissopou EK; Chatzistefanou KI
Ocul Immunol Inflamm; 2023 Dec; 31(10):2001-2008. PubMed ID: 36693268
[TBL] [Abstract][Full Text] [Related]
29. Benefits of Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study.
; Kempen JH; Altaweel MM; Drye LT; Holbrook JT; Jabs DA; Sugar EA; Thorne JE
Ophthalmology; 2015 Oct; 122(10):1967-75. PubMed ID: 26298715
[TBL] [Abstract][Full Text] [Related]
30. The ocular and systemic prognosis of patients presenting with sarcoid uveitis.
Edelsten C; Pearson A; Joynes E; Stanford MR; Graham EM
Eye (Lond); 1999 Dec; 13 ( Pt 6)():748-53. PubMed ID: 10707138
[TBL] [Abstract][Full Text] [Related]
31. Sarcoid Uveitis in Children.
Smith JR; Mochizuki M
Ocul Immunol Inflamm; 2023 Dec; 31(10):1965-1970. PubMed ID: 37983819
[TBL] [Abstract][Full Text] [Related]
32. [Systemic biological treatment in ophthalmology].
Benyó F; Farkas A; Horváth H; Nagy ZZ; Szepessy Z
Orv Hetil; 2019 Nov; 160(44):1744-1750. PubMed ID: 31657252
[TBL] [Abstract][Full Text] [Related]
33. Role of CT Chest and Cytology in Differentiating Tuberculosis from Presumed Sarcoidosis in Uveitis.
Bansal R; Gupta A; Agarwal R; Dogra M; Bhutani G; Gupta V; Dogra MR; Katoch D; Aggarwal AN; Sharma A; Nijhawan R; Nada R; Nahar Saikia U; Dey P; Behera D
Ocul Immunol Inflamm; 2019; 27(7):1041-1048. PubMed ID: 29420114
[No Abstract] [Full Text] [Related]
34. Long-Term Outcomes of Treatment with Biological Agents in Eyes with Refractory, Active, Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis.
Al-Janabi A; El Nokrashy A; Sharief L; Nagendran V; Lightman S; Tomkins-Netzer O
Ophthalmology; 2020 Mar; 127(3):410-416. PubMed ID: 31607412
[TBL] [Abstract][Full Text] [Related]
35. [Uveitis as a presenting manifestation of sarcoidosis: clinical characteritics of a series of 23 cases].
Pruna L; Angioi K; Robin A; Deibener J; Poirson A; Selton J; Mohamed S; Kaminsky P
Rev Med Interne; 2012 Nov; 33(11):615-20. PubMed ID: 22763184
[TBL] [Abstract][Full Text] [Related]
36. Clinical manifestations and risk factors for poor visual outcomes of ocular sarcoidosis in Taiwan.
Lai IW; Lin CP; Hsieh YT; Yeh PT
J Formos Med Assoc; 2022 Aug; 121(8):1560-1566. PubMed ID: 35027256
[TBL] [Abstract][Full Text] [Related]
37. Comparison of conventional immunosuppressive drugs versus anti-TNF-α agents in non-infectious non-anterior uveitis.
Leclercq M; Langlois V; Girszyn N; Le Besnerais M; Benhamou Y; Levesque H; Muraine M; Gueudry J
J Autoimmun; 2020 Sep; 113():102481. PubMed ID: 32586650
[TBL] [Abstract][Full Text] [Related]
38. [Ocular sarcoidosis: What the internist should know?].
Sève P; Kodjikian L; Jamilloux Y
Rev Med Interne; 2018 Sep; 39(9):728-737. PubMed ID: 29037464
[TBL] [Abstract][Full Text] [Related]
39. [Experience in treating uveitis of sarcoid etiology].
Chernysheva MV; Chetin VM
Probl Tuberk; 1996; (5):34-5. PubMed ID: 8984488
[No Abstract] [Full Text] [Related]
40. Sarcoidosis-related Uveitis: Clinical Presentation, Disease Course, and Rates of Systemic Disease Progression After Uveitis Diagnosis.
Ma SP; Rogers SL; Hall AJ; Hodgson L; Brennan J; Stawell RJ; Lim LL
Am J Ophthalmol; 2019 Feb; 198():30-36. PubMed ID: 30243930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
